Bimuno IBAID Prebiotic Pastilles

Bimuno IBAID

Information for Healthcare Professionals: IBAID is a soft, chewable pastille. Scientifically proven to help enhance the gut’s bifidobacterial population.

 

What is Bimuno® IBAID?

Available in the form of chewable pastilles, Bimuno® Intestinal Bifidobacteria Aid (IBAID) has been formulated according to the specific needs of people who wish to actively help maintain their digestive health and is scientifically proven to help enhance the gut’s bifidobacterial population.

Sufferers of irritable bowel syndrome (IBS) generally have lower levels of bifidobacteria compared to normal populations8. Based on the findings of the B-GOS IBS scientific study7, Bimuno® IBAID has been specifically developed to provide the optimum dosage for rebalancing friendly bacteria – particularly bifidobacteria – in the gut, as well as taking into consideration IBS sufferers’ need for a discreet, easy-to-use formulation.

IBS in the UK

Irritable bowel syndrome is the most common functional G.I. disorder1. Depending on the specific criteria used to define IBS, its prevalence in the general adult population of the UK is up to 20%, or one in five2. This equates to 9 million sufferers, of which only about 2.5 million have been diagnosed. For many it is a chronic disorder3, with patients experiencing significant impairment in their productivity and health-related quality of life.

The diagnosis of IBS has importance in both human and economic terms4. The annual health care cost of IBS is high, while patients suffering from severe symptoms can lose significant amounts of time off work.

Why recommend Bimuno® IBAID?

There is considerable discussion around the evidence for restricting the use of rapidly fermentable, short-chain carbohydrates (FODMAPs) in certain groups of people, including IBS sufferers and others with functional gastrointestinal symptoms. Emerging evidence suggests that a low FODMAP diet may be beneficial to IBS sufferers, as it avoids food types that increase bloating and gas production.

The long-term safety implications of a low FODMAP diet have not been evaluated, however, it has been proven that the diet results in a significant decrease in bifidobacteria10. Levels of bifidobacteria –  a health promoting bacteria – in the gut are normally already lower in IBS patients8, and a further reduction of this bacterial group may have a negative effect on the patient's quality of life. 

Bimuno® has been proven to significantly increase bifidobacteria levels in IBS patients7, the elderly11 and other healthy healthy adults12, and as such healthcare professionals may wish to consider adding Bimuno® IBAID to their recommendation when advising patients to follow a low FODMAP diet.

Bimuno® IBAID consists of beta-glucosidic and beta-galactosidic linkages and is fermented by bifidobacterium species, which are known not to produce gas7,9.

The clinical evidence behind Bimuno®

Gut health maintenance and increased bifidobacterial levels: 

  • Bimuno® shown to help maintain gut health7
  • Bimuno® significantly increased bifidobacteria numbers7

Prevention of pathogenic G.I. bacteria colonisation:

  • Bimuno® strongly inhibited the attachment and colonisation of G.I. pathogenic bacteria enteropathogenic Escherichia coli5 and Salmonella Typhimurium5,6.

Gut health maintenance in healthy adults:
Significant gut health maintenance vs placebo and baseline within one week9

Who can benefit from Bimuno® IBAID?

It is ideal for individuals who wish to actively help maintain their digestive health. Bimuno® IBAID could benefit those for whom FODMAPs may not be suitable and those on a low FODMAP diet. Bimuno® is proven to increase bifidobacteria in the gut– an important immunity boosting bacterial group that is decreased by a low FODMAP diet10.

It is suitable for adults and children aged 12 years and over.

Recommending Bimuno® IBAID

Bimuno® IBAID is classed as a food supplement and does not have any of the warnings and contra-indications associated with medicinal products. It is not a medicinal product and is not intended to treat or prevent medical conditions or their symptoms.

Although no adverse effects have been reported, it should be noted that Bimuno® IBAID contains small amounts of lactose (from milk).

The product contains 30 chewable pastilles.

The active ingredient is galacto-oligosaccharides, equivalent to a daily dose of 1.38g. It is free from artificial colours, flavours and preservatives and is gluten free. The lactose content is 0.36g* per daily dose. Per daily dose it contains 13 kcal, 1.6g of sugar and 0.0g of fat.

Recommended Serving:

  • The dosage is two pastilles per day.
  • For best results the two pastilles should be taken after breakfast; take one immediately after the other.
  • Since the benefits build over time, a daily intake is recommended.
  • Suitable for adults and children aged 12 years and over.

* Lactose doses of less than 10g per day are likely
to be tolerated by most of the population of lactose deficient adults. EFSA
Journal (2007) 565, 1-6.

 

References
1. Drossman D et al. Dig Dis Sci 1993;38:1569-1580.
2. Jones R et al. BMJ 1992;304:87-90.
3. Silk DBA. Eur J Gastroenterology & Hepatology 2001;13:1327-1332.
4. Silk DBA. Eur J Gastroenterology & Hepatology 2003;15:679-696.
5. Tzortzis et al. J Nutr 2005;135:1726-1731.
6. Searle LEJ et al. Journal of Medical Microbiology 2009;58:37-48.
7. Silk DBA et al. Aliment Pharmacol Ther 2009;29:508-518.
8. Microbiologica 1982;5:185-194.
9. Awaiting publication.
10. Staudacher HM et al. J.Nutr. 2012;142:1510-1518.
11. Vulevic J et al. Am J Clin Nutr 2008;88:1438-46. 
12. Depeint F et al. Am J Clin Nutr 2005;87:785-91.

 

Back to Healthcare Professionals

Disclaimer

This section is an information and educational resource for healthcare professionals, scientists, researchers and journalists. It is not intended for consumers. If you wish to purchase Bimuno please click here

Back to the top